Transkaryotic Therapies' P2P Acquisition

Transkaryotic Therapies raised a round of funding on April 20, 2005. Investors include Shire.

Transkaryotic Therapies (NASDAQ: TKTX) develops technologies for the production of human proteins and for gene therapy systems. Products developed with these technologies include ReplagalT, a drug app…

Articles about Transkaryotic Therapies' P2P Acquisition: